To The Moon

Some seasoned investment gurus are saying there's still a lot of room for the US stock market to drop. But hey, if the market goes into a tailspin, it might just be the silver lining for these electric vehicle charging stocks like $ChargePoint Holdings Inc.(CHPT)$ $Blink Charging(BLNK)$ $EVgo Inc​.(EVGO)$. Their valuations are likely to hit those irresistibly low buy zones, giving investors a chance to get in on the action at rock-bottom prices.1. ChargePoint $ChargePoint Holdings Inc.(CHPT)$ is one of the world's largest EV charging networks. Its stock price has taken a tumble recently, bringing its price-to-sales rati

With Rinvoq and Skyrizi, these new anti-inflammatory drugs, taking over the throne from Humira, $AbbVie(ABBV)$ has increased its full-year profit forecast in 2024.AbbVie now expects adjusted earnings per share to range from $11.13 to $11.33, exceeding the previous high of $11.17 per share, according to a statement Friday.Abbvie shares fell 1.3% at the start of trading in New York. As of Thursday's close, the stock had risen 8%. The company has been working to fill the void left by Humira after it lost patent protection last year and cheaper biosimilars began eating into market share.Abbvie's new biologic drugs like Skyrizi and Rinvoq have been helping to offset the impact of declining Humira sales. And the company's recent deals in cancer and neur

A lot of quality healthcare stocks offer investors long-term stability, good growth prospects, and even dividends. But $Bristol-Myers Squibb(BMY)$ doesn't quite meet all those criteria.This healthcare stock has been facing some challenges recently, but now it might just be seeing the light at the end of the tunnel. With its undervalued status, this could be a long-term buying opportunity for contrarian investors.The stock has fallen 30% in the past 12 months, thanks to its roughly $37 billion in long-term debt on the company's books in a high-interest rate environment, and the loss of patent protection for Eliquis, Opdivo and Revlimid in the coming years as sales slump. In addition, BMY's revenue fell 3% last year to $45 billion, the second straigh

With the continuous advancement of AI technology, more innovative medical applications will inevitably emerge in the future. $Recursion Pharmaceuticals, Inc.(RXRX)$ partnered with chipmaker $NVIDIA Corp(NVDA)$ in 2023 to conduct AI-led drug development, and the company's stock surged after the announcement.On Wednesday, $Moderna, Inc.(MRNA)$ , the developer of the COVID-19 vaccine, announced a partnership with OpenAI to deploy the AI company's ChatGPT Enterprise in its business to accelerate drug development.According to the collaboration agreement, approximately 3,000 Moderna employees will have access to ChatGPT Enterprise, built on OpenAI's cutting-edge langua

These three stocks have already made a ton of millionaires, and they're probably going to make even more! So, Is it too late to add them to the portfolio?1.Constellation Software $Constellation Software, Inc.(CNSWF)$ is a powerhouse in acquiring leading software and services in the market. Their revenue has skyrocketed to $8 billion in 2023. With a strategy that combines organic growth and acquisitions, they've transformed into an international professional solutions provider. From 2007 to 2023, Constellation's stock price has seen an equally impressive transformation. Shares have soared from around $23 to the current $3,720, an increase of more than 16,000%. Obviously, many millionaires have been born.2.Shopify

AI stocks are stealing the spotlight from other emerging technologies, including quantum computing stocks. But don't worry, the explosion of quantum computing stocks in the US market is just a matter of time. According to BCC Research, this market is expected to grow at a whopping 48.1% CAGR from 2022 to 2028, reaching a whopping $6.5 billion!Here are three quantum computing stocks in the US market that combine stability with upside potential:1.IBM $IBM(IBM)$ is a pioneer in the quantum computing space. IBM Quantum is a world leader in building quantum hardware and plays a crucial role in commercializing this technology. Their goal? To effectively scale quantum computing to solve complex problems, reduce error rates, and develop industry-specific a

The bull market in the US stock market is essentially a bull market for these seven giants of tech with huge market caps. But the biggest investors in the US, those ginormous fund management companies, can't pile on the "Magnificent Seven" because they're bound by the rules of "diversification".However, these funds are willing to ditch their "diversification" status and pump up their holdings in the "Magnificent Seven", unleashing a fresh wave of investment funds flooding into these behemoth stocks. $HSBC Holdings PLC(HSBC)$ did some digging and found that almost every US fund manager- those with assets under management (AUM) of more than $1.9 trillion - underweights the "Magnificent Seven". Specifically, while the "Magnificent Seven" -

Shares of three biotech stocks, $Viking Therapeutics(VKTX)$ $Skye Bioscience Inc.(SKYE)$ $Janux Therapeutics, Inc.(JANX)$, have surged at least 269% so far this year. Do they have room to rise?1.Viking Therapeutics Since $Novo-Nordisk A/S(NVO)$ and $Eli Lilly(LLY)$ launched their own weight-loss treatments, both stocks have surged. VKTX is working on a GLP-1 therapeutic oral solution called VK2735. In Phase II trials, VK2735 performed even better than NVO's Wegovy or LLY's Zepbound.VKTX shares are up 269% year-to-date and could rise even higher as VK2735 advances in late-stage tri

On Monday, all three major US stock indices gave up their intraday gains and closed in the red. The $S&P 500(.SPX)$ fell 1.2% and below 5,100 points, marking a 2.6% decline over two trading sessions - the steepest drop in more than a year.Additionally, the $DJIA(.DJI)$ dipped 0.7%, and the $NASDAQ(.IXIC)$ tumbled 1.8%, with large-cap tech stocks taking the lead in the sell-off. $Microsoft(MSFT)$ $Apple(AAPL)$ and $NVIDIA Corp(NVDA)$ were among the top losers in the interest rate-sensitive tech sector.Almost all the stocks in the

图片 $Goldman Sachs(GS)$ is taking some profits out of soaring tech stocks and redirecting them towards lower-cost companies. A recent analysis shows that the combined market value of the "Magnificent Seven" has exceeded $13 trillion.Alexandra Wilson-Elizondo, co-chief investment officer of Goldman Sachs Multi-Asset Solutions, said the firm believes tech stocks will be under pressure, and is more optimistic about areas like energy and Japanese stocks. In her view, the US economy is heading towards a soft landing, but there are plenty of risks that could change that trajectory.She added:We love taking profits in tech and moving them to other sectors. In tech, the risk-reward ratio is tipping towards the downside. While we still believe in being long st